1. Home
  2. CCJ vs WAT Comparison

CCJ vs WAT Comparison

Compare CCJ & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cameco Corporation

CCJ

Cameco Corporation

HOLD

Current Price

$87.05

Market Cap

45.6B

ML Signal

HOLD

Logo Waters Corporation

WAT

Waters Corporation

HOLD

Current Price

$376.47

Market Cap

23.0B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCJ
WAT
Founded
1987
1958
Country
Canada
United States
Employees
N/A
N/A
Industry
Other Metals and Minerals
Biotechnology: Laboratory Analytical Instruments
Sector
Basic Materials
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
45.6B
23.0B
IPO Year
N/A
1995

Fundamental Metrics

Financial Performance
Metric
CCJ
WAT
Price
$87.05
$376.47
Analyst Decision
Buy
Buy
Analyst Count
6
15
Target Price
$114.38
$388.67
AVG Volume (30 Days)
4.0M
544.8K
Earning Date
11-05-2025
11-04-2025
Dividend Yield
0.19%
N/A
EPS Growth
364.36
3.82
EPS
0.87
10.88
Revenue
$2,487,042,049.00
$3,105,638,000.00
Revenue This Year
$10.12
$7.96
Revenue Next Year
$6.89
$6.32
P/E Ratio
$105.47
$35.43
Revenue Growth
23.88
6.90
52 Week Low
$35.00
$275.05
52 Week High
$110.16
$423.56

Technical Indicators

Market Signals
Indicator
CCJ
WAT
Relative Strength Index (RSI) 45.26 43.71
Support Level $88.79 $385.08
Resistance Level $96.57 $397.55
Average True Range (ATR) 3.66 9.29
MACD 0.01 -4.03
Stochastic Oscillator 6.48 0.00

Price Performance

Historical Comparison
CCJ
WAT

About CCJ Cameco Corporation

Cameco Corp is a provider of uranium needed to generate clean, reliable baseload electricity around the globe. one of those uranium producers. It has three reportable segments, Uranium, Fuel Services, and Westinghouse. It derives maximum revenue from the Westinghouse Segment. It has some projects namely; Millennium, Yeelirrie, Kintyre, and Exploration. The company operates in Canada, Kazakhstan, Germany, Australia, and the United States.

About WAT Waters Corporation

Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.

Share on Social Networks: